🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "huge turning point" in the fight against superbug strains of the infection, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting more than 82 million instances annually. Notably increased rates are reported in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the face of rising global incidence, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Medical experts are increasingly worried about the increase in antibiotic-resistant strains. The WHO has classified it as a "critical concern". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

One new antibiotic, also known as Nuzolvence, was authorized by the American regulatory agency in December for combating gonorrhoea. This infection can lead to major issues, including infertility. Researchers anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a innovative non-profit model for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This approval represents a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Outcomes and Worldwide Availability

According to data published in a major medical journal, the new drug eradicated over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which involves a dual-drug approach. The research involved hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians directly involved have shared positive views. Access to a one-pill regimen such as this is hailed as a "game-changer" for public health efforts. This is viewed as essential to alleviate the strain of the illness for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.